drugset
Drugs / IMMUNEPOTENT-CRP (I-CRP)
last change Mar 2022 re-read 3 minutes ago

IMMUNEPOTENT-CRP (I-CRP)

Peptide

Developed for
COVID-19
Investigated by
Autonomous University of Nuevo León · Hospital Universitario Dr. Jose E. Gonzalez · Laboratorio de Inmunologia y Virologia - UANL

Trials 1

today NCT06676709 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06676709 Apr 2021 → Feb 2022 COVID-19 Autonomous University of Nuevo León Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IMMUNEPOTENT-CRP (I-CRP) ClinicalTrials.gov intervention name — accepted as the source's own label NCT06676709 ↗
Modality Peptide “mixture of low-molecular-weight peptides” NCT06676709 ↗